

QUESTIONS ON THE PRESENTATION

“Risperidone Case 1 Drug-Drug Interactions” (01-14-16)

Please select the single best choice.

1. An *in vitro* study demonstrates that adding carbamazepine increases risperidone’s metabolic activity on CYP in hepatic cells. This is a pharmacodynamic study.
 - A. True
 - B. False
2. Adding carbamazepine to a polypharmacy regimen may decrease the efficacy of some drugs.
 - A. True
 - B. False
3. Discontinuing carbamazepine from a polypharmacy regimen may increase the risk for adverse drug reactions with the remaining drugs after 2-3 weeks.
 - A. True
 - B. False
4. Regarding risperidone metabolism:
 - A. CYP2D6 is the only clinically relevant CYP isoenzyme.
 - B. Carbamazepine induces CYP2D6.
 - C. CYP3A4 activity level is not important.
 - D. None of the above is correct.
5. A placebo-controlled 2003 study that added risperidone as an adjuvant treatment for mania:
 - A. Found that risperidone was more effective than placebo in patients taking valproate and lithium.
 - B. Found that risperidone was not more effective than placebo in patients taking carbamazepine.
 - C. Contributed to the finding that patients on carbamazepine may need higher-than-average risperidone doses.
 - D. All of the above are correct.

6. "Risperidone follows linear kinetics" means:
- A. There is a linear relationship between risperidone dose (D) and concentration (C).
 - B. The ratio between C/D can be represented by a line.
 - C. If the D increases by two times, the C increases by two times.
 - D. All of the above are correct.
7. Regarding risperidone therapeutic drug monitoring:
- A. The therapeutic concentration (C) is calculated by adding serum risperidone and 9-hydroxyrisperidone concentrations.
 - B. Risperidone and 9-hydroxyrisperidone are described by the pharmaceutical marketer to be equally potent.
 - C. It can be used to explore risperidone metabolism in patients.
 - D. All of the above are correct.
8. With 5 mg/day of risperidone, the steady-state serum concentrations are 3 ng/ml for risperidone and 32 ng/ml for 9-hydroxyrisperidone. The C/D ratio is:
- A. 5.
 - B. $5/35=0.14$.
 - C. $3+32/5=7$.
 - D. $5/3=1.66$.
9. Smoking influences risperidone metabolism.
- A. True
 - B. False
10. Therapeutic drug monitoring may be helpful in unexplained cases of lack of efficacy.
- A. True
 - B. False